Danli Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Danli Yang has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Yeli Li
Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou, China
5 shared publicationsShu Fu
Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou, China
4 shared publicationsYe-Li Li
Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, China
4 shared publicationsYun Yue
Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Key Laboratory of Basic Pharmacology of Guizhou Province, Department of Pharmacology, School of Pharmacy, Zunyi Medical University , Zunyi, Guizhou
4 shared publications- Yu Wang
Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, PR China; School of Pharmacy, Zunyi Medical University, Zunyi, PR China
3 shared publications - Yuting Wu
Institute for Cardiovascular Prevention (C.A.B., M.L., V.T., F.M.F., K.N., Y.W., V.B., I.A-K., Y.F.S.M., M.K., K.R., C.W., D.S., E.L., D.A.), Ludwig Maximilians Universität, Munich, Germany
3 shared publications
Latest Publications
- 24 March 2026
- Published by Elsevier in Fitoterapia
- Vol. 190, 107183
Corrigendum to “Decoding the heart-saving power of Sanweidoukou decoction: Mitochondrial and molecular insights” [Fitoterapia 190 (2026) 107134]
- 24 March 2026
- Published by Elsevier in Fitoterapia
- Vol. 190, 107183
Corrigendum to “Decoding the heart-saving power of Sanweidoukou decoction: Mitochondrial and molecular insights” [Fitoterapia 190 (2026) 107134]
- 11 February 2026
- Published by Elsevier in Fitoterapia
- Vol. 190, 107134
Decoding the heart-saving power of Sanweidoukou decoction: Mitochondrial and molecular insights
- 11 February 2026
- Published by Elsevier in Fitoterapia
- Vol. 190, 107134
Decoding the heart-saving power of Sanweidoukou decoction: Mitochondrial and molecular insights
- Open Access
- 12 March 2024
- Published by Herald Scholarly Open Access in Journal of Alternative, Complementary & Integrative Medicine
- Vol. 10 (2) , 1-7
The Effect of Colchicine on Cardiac Dysfunction in Isoproterenol-Induced Mice: Insights into the Role of PGC-1α / PPARα Signaling Pathway
In conclusion, colchicine exhibits a therapeutic potential in ameliorating cardiac dysfunction in isoproterenol-induced mice, potentially mediated, at least in part, by enhancing the activity of PGC-1α, PPARα, CPT-1α, and MCAD and to enhance the fatty acid β-oxidation.
- 12 March 2024
- Published by Herald Scholarly Open Access in Journal of Alternative, Complementary & Integrative Medicine
- Vol. 10 (2) , 1-7
Open AccessThe Effect of Colchicine on Cardiac Dysfunction in Isoproterenol-Induced Mice: Insights into the Role of PGC-1α / PPARα Signaling Pathway
In conclusion, colchicine exhibits a therapeutic potential in ameliorating cardiac dysfunction in isoproterenol-induced mice, potentially mediated, at least in part, by enhancing the activity of PGC-1α, PPARα, CPT-1α, and MCAD and to enhance the fatty acid β-oxidation.
- 11 February 2022
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 80 (1) , 48-55
Icariside II Attenuates Vascular Remodeling Via Wnt7b/CCND1 Axis
Angioplasty often fails due to the abnormal proliferation of vascular smooth muscle cells (VSMCs). Success rates of angioplasty may increase following the administration of an agent that effectively ameliorates aberrant vascular remodeling. Icariside II (ICS-II) is a natural flavonol glycoside extract from the Chinese herbal medicine Epimedii that possesses several medicinal qualities that are beneficial in humans. Nevertheless, the role of ICS-II in addressing aberrant vascular remodeling have yet to be clarified. The current investigation studies the molecular effects of ICS-Ⅱ on balloon-inflicted neointimal hyperplasia in rats in vivo and on platelet-derived growth factor–induced vascular proliferation in primary rat aortic smooth muscle cells (VSMCs) in vitro. ICS-II was found to be as effective as rapamycin, the positive control used in this study. ICS-II inhibited neointimal formation in injured rat carotid arteries and notably reduced the expression of Wnt7b. ICS-Ⅱ significantly counteracted platelet-derived growth factor–induced VSMCs proliferation. Cell cycle analysis showed that ICS-II triggered cell cycle arrest during the G1/S transition. Western blot analysis further indicated that this cell cycle arrest was likely through Wnt7b suppression that led to CCND1 inhibition. In conclusion, our findings demonstrate that ICS-II possesses significant antiproliferative qualities that counteracts aberrant vascular neointimal hyperplasia. This phenomenon most likely occurs due to the suppression of the Wnt7b/CCND1 axis.
- 11 February 2022
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 80 (1) , 48-55
Icariside II Attenuates Vascular Remodeling Via Wnt7b/CCND1 Axis
Angioplasty often fails due to the abnormal proliferation of vascular smooth muscle cells (VSMCs). Success rates of angioplasty may increase following the administration of an agent that effectively ameliorates aberrant vascular remodeling. Icariside II (ICS-II) is a natural flavonol glycoside extract from the Chinese herbal medicine Epimedii that possesses several medicinal qualities that are beneficial in humans. Nevertheless, the role of ICS-II in addressing aberrant vascular remodeling have yet to be clarified. The current investigation studies the molecular effects of ICS-Ⅱ on balloon-inflicted neointimal hyperplasia in rats in vivo and on platelet-derived growth factor–induced vascular proliferation in primary rat aortic smooth muscle cells (VSMCs) in vitro. ICS-II was found to be as effective as rapamycin, the positive control used in this study. ICS-II inhibited neointimal formation in injured rat carotid arteries and notably reduced the expression of Wnt7b. ICS-Ⅱ significantly counteracted platelet-derived growth factor–induced VSMCs proliferation. Cell cycle analysis showed that ICS-II triggered cell cycle arrest during the G1/S transition. Western blot analysis further indicated that this cell cycle arrest was likely through Wnt7b suppression that led to CCND1 inhibition. In conclusion, our findings demonstrate that ICS-II possesses significant antiproliferative qualities that counteracts aberrant vascular neointimal hyperplasia. This phenomenon most likely occurs due to the suppression of the Wnt7b/CCND1 axis.
- Open Access
- 14 May 2021
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 73 (8) , 1109-1117
Osthole improves pulmonary artery hypertension by inducing apoptosis in pulmonary artery smooth muscle cells
The objectives of this study were to explore the effect of Osthole (Ost) on apoptosis in pulmonary artery smooth muscle cells (PASMCs) and investigate the potential mechanism of this effect. Rats were injected subcutaneously with monocrotaline (MCT) to establish a PAH model, and Ost were intragastrically administrated from day 1 to day 35. After 35 days administration, the mean pulmonary artery pressure and lung weight index were measured. HE and TUNEL staining were used to observe the morphology of pulmonary artery and the apoptosis of PASMCs. In addition, the apoptosis of PASMCs were detected by flow cytometry in cultured PASMCs. The proteins of Bax and Bcl-2, and the levels of p-ASK1 and cleaved caspase 3 were measured by Western blot. Ost decreased the mean pulmonary artery pressure and lung weight index in MCT-induced rats, and promoted apoptosis in PASMCs in MCT-induced rats and PDGF-BB stimulated PASMCs. Ost increased the ratio of Bax/Bcl-2 and the levels of p-ASK1, cleaved caspase 3 in MCT-induced rats and PDGF-BB stimulated PASMCs. Ost promoted apoptosis in PASMCs in vivo and in vitro, and the mechanism may be associated with upregulation of ASK1 and the Bax/Bcl-2-caspase 3 signalling pathway.
- 14 May 2021
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 73 (8) , 1109-1117
Open AccessOsthole improves pulmonary artery hypertension by inducing apoptosis in pulmonary artery smooth muscle cells
The objectives of this study were to explore the effect of Osthole (Ost) on apoptosis in pulmonary artery smooth muscle cells (PASMCs) and investigate the potential mechanism of this effect. Rats were injected subcutaneously with monocrotaline (MCT) to establish a PAH model, and Ost were intragastrically administrated from day 1 to day 35. After 35 days administration, the mean pulmonary artery pressure and lung weight index were measured. HE and TUNEL staining were used to observe the morphology of pulmonary artery and the apoptosis of PASMCs. In addition, the apoptosis of PASMCs were detected by flow cytometry in cultured PASMCs. The proteins of Bax and Bcl-2, and the levels of p-ASK1 and cleaved caspase 3 were measured by Western blot. Ost decreased the mean pulmonary artery pressure and lung weight index in MCT-induced rats, and promoted apoptosis in PASMCs in MCT-induced rats and PDGF-BB stimulated PASMCs. Ost increased the ratio of Bax/Bcl-2 and the levels of p-ASK1, cleaved caspase 3 in MCT-induced rats and PDGF-BB stimulated PASMCs. Ost promoted apoptosis in PASMCs in vivo and in vitro, and the mechanism may be associated with upregulation of ASK1 and the Bax/Bcl-2-caspase 3 signalling pathway.
- Open Access
- 4 January 2021
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 73 (2) , 145-151
Sildenafil improves right ventricular remodelling in monocrotaline-induced rats by decreasing myocardial apoptosis and activating peroxisome proliferator-activated receptors
Objectives: To assess the effect of sildenafil on monocrotaline-induced right ventricular (RV) remodeling and investigate the possible mechanism. Methods: Rats were subcutaneously injected with monocrotaline to establish an RV remodeling model and then administered sildenafil (25 mg/kg) from days 1 to 28. After 28 days of administration, the RV systolic pressure and the RV hypertrophy index (RVHI) were measured. The morphology of the right ventricle was observed by H&E staining. The ultrastructure of the right ventricle was observed using a transmission electron microscope. The myocardial apoptosis of the right ventricle was evaluated by TUNEL staining. The protein expression of apoptosis-related proteins and PPARs were examined by western blotting. Key findings: The results indicated that sildenafil decreased the RV systolic pressure and RVHI, and improved the microstructure and ultrastructure of the right ventricle in monocrotaline-induced rats. In addition, sildenafil suppressed myocardial apoptosis and promoted the protein expression of PPARs of the right ventricle in monocrotaline-induced rats. Conclusion: Sildenafil inhibits RV remodeling in monocrotaline-induced rats, which might be partially mediated by reducing myocardial apoptosis and activating PPARs.
- 4 January 2021
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 73 (2) , 145-151
Open AccessSildenafil improves right ventricular remodelling in monocrotaline-induced rats by decreasing myocardial apoptosis and activating peroxisome proliferator-activated receptors
Objectives: To assess the effect of sildenafil on monocrotaline-induced right ventricular (RV) remodeling and investigate the possible mechanism. Methods: Rats were subcutaneously injected with monocrotaline to establish an RV remodeling model and then administered sildenafil (25 mg/kg) from days 1 to 28. After 28 days of administration, the RV systolic pressure and the RV hypertrophy index (RVHI) were measured. The morphology of the right ventricle was observed by H&E staining. The ultrastructure of the right ventricle was observed using a transmission electron microscope. The myocardial apoptosis of the right ventricle was evaluated by TUNEL staining. The protein expression of apoptosis-related proteins and PPARs were examined by western blotting. Key findings: The results indicated that sildenafil decreased the RV systolic pressure and RVHI, and improved the microstructure and ultrastructure of the right ventricle in monocrotaline-induced rats. In addition, sildenafil suppressed myocardial apoptosis and promoted the protein expression of PPARs of the right ventricle in monocrotaline-induced rats. Conclusion: Sildenafil inhibits RV remodeling in monocrotaline-induced rats, which might be partially mediated by reducing myocardial apoptosis and activating PPARs.
- 9 December 2019
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 72 (2) , 227-235
Icariside II improves myocardial fibrosis in spontaneously hypertensive rats by inhibiting collagen synthesis
Objectives We aimed to investigate the effects of icariside II (ICS II) on myocardial fibrosis in spontaneously hypertensive rats (SHRs) and to explore the possible mechanisms. Methods We used SHRs as animal models, and we administered ICS II (4, 8 or 16 mg/kg) orally by gavage for 12 consecutive weeks (Fu et al., Biomed Pharmacother 2018; 100: 64). The left ventricular morphology of the rats was observed using haematoxylin–eosin (HE) staining. The occurrence of myocardial interstitial fibrosis was detected by Masson's trichrome staining. The protein levels of alpha smooth muscle actin (α‐SMA), Collagen I, III, matrix metalloproteinases 2 and 9 (MMP‐2 and MMP‐9, respectively), tissue inhibitor of metalloproteinase 1 (TIMP‐1), transforming growth factor‐β1 (TGF‐β1), phospho‐Smad2 (p‐Smad2), phospho‐Smad3 (p‐Smad3) and phospho‐p38 (p‐p38) were examined by Western blotting. Key findings The results suggested that ICS II improved myocardial interstitial and perivascular collagen deposition and decreased Collagen I/III and α‐SMA expression. ICS II (8 and 16 mg/kg) downregulated the expression of MMP‐2 and MMP9 and upregulated the expression of TIMP1. In addition, the protein levels of p‐Smad2/3, TGF‐β1 and p‐p38 were decreased by ICS II treatment. Conclusions The results suggest that ICS II can inhibit the expression of Collagen I and Collagen III through the MMP/TIMP‐1 and TGF‐β1/Smad2,3/p‐p38 signalling pathways and that it has therapeutic effects on myocardial fibrosis.
- 9 December 2019
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 72 (2) , 227-235
Icariside II improves myocardial fibrosis in spontaneously hypertensive rats by inhibiting collagen synthesis
Objectives We aimed to investigate the effects of icariside II (ICS II) on myocardial fibrosis in spontaneously hypertensive rats (SHRs) and to explore the possible mechanisms. Methods We used SHRs as animal models, and we administered ICS II (4, 8 or 16 mg/kg) orally by gavage for 12 consecutive weeks (Fu et al., Biomed Pharmacother 2018; 100: 64). The left ventricular morphology of the rats was observed using haematoxylin–eosin (HE) staining. The occurrence of myocardial interstitial fibrosis was detected by Masson's trichrome staining. The protein levels of alpha smooth muscle actin (α‐SMA), Collagen I, III, matrix metalloproteinases 2 and 9 (MMP‐2 and MMP‐9, respectively), tissue inhibitor of metalloproteinase 1 (TIMP‐1), transforming growth factor‐β1 (TGF‐β1), phospho‐Smad2 (p‐Smad2), phospho‐Smad3 (p‐Smad3) and phospho‐p38 (p‐p38) were examined by Western blotting. Key findings The results suggested that ICS II improved myocardial interstitial and perivascular collagen deposition and decreased Collagen I/III and α‐SMA expression. ICS II (8 and 16 mg/kg) downregulated the expression of MMP‐2 and MMP9 and upregulated the expression of TIMP1. In addition, the protein levels of p‐Smad2/3, TGF‐β1 and p‐p38 were decreased by ICS II treatment. Conclusions The results suggest that ICS II can inhibit the expression of Collagen I and Collagen III through the MMP/TIMP‐1 and TGF‐β1/Smad2,3/p‐p38 signalling pathways and that it has therapeutic effects on myocardial fibrosis.
- 20 November 2018
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 71 (3) , 400-407
Icariside II prevents hypertensive heart disease by alleviating endoplasmic reticulum stress via the PERK/ATF-4/CHOP signalling pathway in spontaneously hypertensive rats
Objectives: Reducing endoplasmic reticulum stress (ERS)-induced cardiomyocyte apoptosis is a key strategy for preventing hypertensive heart disease. In our previous study, Icariside II can improve left ventricular remodelling in spontaneously hypertensive rats (SHRs). This study aims to determine whether Icariside II can exert its effect by inhibiting ERS-induced cardiomyocyte apoptosis via the PERK/ATF-4/CHOP signalling pathway. Methods: Spontaneously hypertensive rats were randomly divided into model group and Icariside II groups. The rats in the Icariside II groups were intragastrically administrated with Icariside II 4, 8 and 16 mg/kg from 14 to 26 week-age, respectively. The left ventricular function was measured at the 18, 22 and 26 week-age by small animal ultrasound. At the end of the 26th week, cardiomyocyte apoptosis was analysed and the levels of GRP78, PERK, ATF-4 and CHOP gene and protein were detected. Key findings: The function of left ventricular became declined with age in SHRs, but improved in Icariside II groups. Myocardial apoptosis was aggravated in SHRs, but alleviated in Icariside II groups. Icariside II could reduce the levels of GRP78, PERK, ATF-4, CHOP gene and protein that increased in SHRs. Conclusions: Icariside II prevents hypertensive heart disease by alleviating ERS-induced cardiomyocyte apoptosis, and its mechanism is related to the impediment of the PERK/ATF-4/CHOP signalling pathway.
- 20 November 2018
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 71 (3) , 400-407
Icariside II prevents hypertensive heart disease by alleviating endoplasmic reticulum stress via the PERK/ATF-4/CHOP signalling pathway in spontaneously hypertensive rats
Objectives: Reducing endoplasmic reticulum stress (ERS)-induced cardiomyocyte apoptosis is a key strategy for preventing hypertensive heart disease. In our previous study, Icariside II can improve left ventricular remodelling in spontaneously hypertensive rats (SHRs). This study aims to determine whether Icariside II can exert its effect by inhibiting ERS-induced cardiomyocyte apoptosis via the PERK/ATF-4/CHOP signalling pathway. Methods: Spontaneously hypertensive rats were randomly divided into model group and Icariside II groups. The rats in the Icariside II groups were intragastrically administrated with Icariside II 4, 8 and 16 mg/kg from 14 to 26 week-age, respectively. The left ventricular function was measured at the 18, 22 and 26 week-age by small animal ultrasound. At the end of the 26th week, cardiomyocyte apoptosis was analysed and the levels of GRP78, PERK, ATF-4 and CHOP gene and protein were detected. Key findings: The function of left ventricular became declined with age in SHRs, but improved in Icariside II groups. Myocardial apoptosis was aggravated in SHRs, but alleviated in Icariside II groups. Icariside II could reduce the levels of GRP78, PERK, ATF-4, CHOP gene and protein that increased in SHRs. Conclusions: Icariside II prevents hypertensive heart disease by alleviating ERS-induced cardiomyocyte apoptosis, and its mechanism is related to the impediment of the PERK/ATF-4/CHOP signalling pathway.
- 1 January 2018
- Published by Elsevier in European Journal of Pharmacology
- Vol. 819, 68-79
IcarisideII improves left ventricular remodeling in spontaneously hypertensive rats by inhibiting the ASK1-JNK/p38 signaling pathway
- 1 January 2018
- Published by Elsevier in European Journal of Pharmacology
- Vol. 819, 68-79
IcarisideII improves left ventricular remodeling in spontaneously hypertensive rats by inhibiting the ASK1-JNK/p38 signaling pathway